Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Loxo Oncology Inc (LOXO): Deerfield Management Discloses 13.65% Activist Stake

Samuel Isaly‘s Orbimed Advisors has disclosed holding a stake in Loxo Oncology Inc (NASDAQ:LOXO). The fund reported buying 275,385 shares in an open-market transaction, at a price of $13 apiece, while another 1.90 million shares have been obtained through the conversion of Series A convertible preferred stock. In this way, Orbimed currently holds around 2.18 million shares of Loxo Oncology Inc (NASDAQ:LOXO), the activist stake amassing 13.65% of the company’s common stock.

Loxo Oncology

Orbimed Advisors also was one of the investors of the company before it went public, being mentioned among the principal stockholders, in Loxo Oncology’s S-1 filing with the SEC. Loxo Oncology Inc (NASDAQ:LOXO) is a small cap healthcare company, engaged in the development of small molecule therapeutics for targeted treatment of cancer. The company went public at the beginning of the month. James Flynn‘s Deerfield Management has also reported a stake in Loxo Oncology Inc (NASDAQ:LOXO), disclosing ownership of 1.59 million shares, its passive stake being equal to almost 10% of the company’s outstanding stock.

Disclosure: none

Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!